KLCM Advisors Inc. Has $18.96 Million Stock Position in Organon & Co. (NYSE:OGN)

Key Points

• KLCM Advisors Inc. increased its stake in Organon & Co. by 3.7% in the first quarter, now owning over 1.27 million shares valued at approximately $18.96 million.
• Organon & Co. reported a quarterly EPS of $1.00, exceeding the expected $0.94, while its quarterly revenue reached $1.59 billion.
• The company recently announced a quarterly dividend of $0.02 per share, with an annualized yield of 0.9%, reflecting a dividend payout ratio of 2.97%.

KLCM Advisors Inc. boosted its position in Organon & Co. (NYSE:OGN - Free Report) by 3.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,273,599 shares of the company's stock after buying an additional 45,950 shares during the quarter. Organon & Co. makes up about 2.2% of KLCM Advisors Inc.'s holdings, making the stock its 9th largest position. KLCM Advisors Inc. owned about 0.49% of Organon & Co. worth $18,964,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. Hsbc Holdings PLC grew its position in shares of Organon & Co. by 13.9% in the fourth quarter. Hsbc Holdings PLC now owns 13,922 shares of the company's stock valued at $208,000 after purchasing an additional 1,703 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Organon & Co. by 28.6% in the fourth quarter. Wells Fargo & Company MN now owns 262,746 shares of the company's stock valued at $3,920,000 after purchasing an additional 58,378 shares in the last quarter. NBC Securities Inc. grew its position in shares of Organon & Co. by 111,262.5% in the first quarter. NBC Securities Inc. now owns 8,909 shares of the company's stock valued at $132,000 after purchasing an additional 8,901 shares in the last quarter. Sequoia Financial Advisors LLC grew its position in shares of Organon & Co. by 42.2% in the first quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company's stock valued at $289,000 after purchasing an additional 5,758 shares in the last quarter. Finally, M&T Bank Corp boosted its stake in Organon & Co. by 3.4% during the first quarter. M&T Bank Corp now owns 55,990 shares of the company's stock valued at $833,000 after buying an additional 1,854 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on OGN. Piper Sandler dropped their price target on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Evercore ISI lowered Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. BNP Paribas raised Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Finally, Morgan Stanley dropped their price target on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Organon & Co. currently has an average rating of "Moderate Buy" and an average price target of $18.00.

Organon & Co. Trading Up 0.4%

Shares of NYSE OGN traded up $0.04 during midday trading on Friday, reaching $9.43. The company had a trading volume of 3,048,686 shares, compared to its average volume of 4,732,525. Organon & Co. has a one year low of $8.01 and a one year high of $23.10. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98. The firm's fifty day moving average price is $9.75 and its 200-day moving average price is $11.63. The stock has a market cap of $2.45 billion, a PE ratio of 3.51, a price-to-earnings-growth ratio of 0.98 and a beta of 0.60.

Organon & Co. (NYSE:OGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, beating analysts' consensus estimates of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. During the same quarter in the previous year, the company posted $1.12 EPS. Organon & Co.'s revenue for the quarter was down .8% on a year-over-year basis. On average, equities research analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Shareholders of record on Friday, August 15th will be given a dividend of $0.02 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a yield of 0.8%. Organon & Co.'s dividend payout ratio is presently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.